Transdermal Drug Delivery Systems (TDDS) Market - Forecasts from 2019 to 2024
The transdermal drug delivery systems (TDDS) market is expected to reach US$49.370 billion by 2024 from US$37.790 billion in 2018 growing at a CAGR of 4.56%. Transdermal drug delivery involves delivering medications in systemic circulation through the skin at a controlled rate, thereby, maintaining effective plasma level concentration of the drug in the body over a prolonged period of time. The drugs are usually applied in the form of an ointment, patches or plaster which is then absorbed into the systemic circulation. Certain factors are taken into consideration while delivering drugs through the skin, this includes skin age, condition, physicochemical factors, and environmental factors. The drug delivery is non-invasive and bypass first-pass metabolism, thus, increasing the bioavailability of the drug. The market growth is attributed to the growing adoption of the TDDS due to the various advantages offered by TDDS which include prolonged therapeutic effect, reduced side-effects, improved bioavailability, better patient compliance and easy termination of drug therapy. However, the inability of the skin to absorb a large range of medications will restrain the market during the forecast period.
DRIVERS
Prevalence of chronic diseases.
Technological advancements.
Increasing health expenditure worldwide.
RESTRAINTS
Stringent regulations regarding the approval of medical devices.
INDUSTRY UPDATE
On January 10, 2017, 3M Drug Delivery Systems announced that it has entered into a new phase of an ongoing collaboration with Panacea Pharmaceuticals, Inc. on new cancer vaccine to be delivered directly into the dermis/skin through 3M™ Hollow Microstructured Transdermal System (HMTS).
On 21st May 2019, Mercia Technologies PLC invested ?2 million in the Medherant Limited which is the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases with its unique TEPI Patch® technology.
The major players profiled in the global transdermal drug delivery systems (TDDS)market include 3M, ProSolus, Inc., Zosano Pharma Corporation, Medherant Limited, Tapemark, Toyochem Co. Ltd., Delivra Corp, Epinamics GmbH, and AdhexPharma among others.
Segmentation
The global transdermal drug delivery systems (TDDS) market has been analyzed through the following segments:
By Type
Patches
Gels and Ointments
By Application
Neurologic Conditions
Pain Management
Nicotine Cessation
Cardiovascular
Others
By End-User
Hospitals and Clinics
Surgical Centers
Home Care Settings
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
DRIVERS
Prevalence of chronic diseases.
Technological advancements.
Increasing health expenditure worldwide.
RESTRAINTS
Stringent regulations regarding the approval of medical devices.
INDUSTRY UPDATE
On January 10, 2017, 3M Drug Delivery Systems announced that it has entered into a new phase of an ongoing collaboration with Panacea Pharmaceuticals, Inc. on new cancer vaccine to be delivered directly into the dermis/skin through 3M™ Hollow Microstructured Transdermal System (HMTS).
On 21st May 2019, Mercia Technologies PLC invested ?2 million in the Medherant Limited which is the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases with its unique TEPI Patch® technology.
The major players profiled in the global transdermal drug delivery systems (TDDS)market include 3M, ProSolus, Inc., Zosano Pharma Corporation, Medherant Limited, Tapemark, Toyochem Co. Ltd., Delivra Corp, Epinamics GmbH, and AdhexPharma among others.
Segmentation
The global transdermal drug delivery systems (TDDS) market has been analyzed through the following segments:
By Type
Patches
Gels and Ointments
By Application
Neurologic Conditions
Pain Management
Nicotine Cessation
Cardiovascular
Others
By End-User
Hospitals and Clinics
Surgical Centers
Home Care Settings
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY TYPE
5.1. Patches
5.2. Gels and Ointments
6. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY APPLICATION
6.1. Neurologic Conditions
6.2. Pain Management
6.3. Nicotine Cessation
6.4. Cardiovascular
6.5. Others
7. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY END-USER
7.1. Hospitals and Clinics
7.2. Surgical Centers
7.3. Home Care Settings
8. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. United Kingdom
8.3.2. Germany
8.3.3. France
8.3.4. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. 3M
10.2. ProSolus, Inc.
10.3. Zosano Pharma Corporation
10.4. Medherant Limited
10.5. Tapemark
10.6. Toyochem Co. Ltd.
10.7. Delivra Corp
10.8. Epinamics GmbH
10.9. AdhexPharma
LIST OF FIGURES
LIST OF TABLES
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY TYPE
5.1. Patches
5.2. Gels and Ointments
6. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY APPLICATION
6.1. Neurologic Conditions
6.2. Pain Management
6.3. Nicotine Cessation
6.4. Cardiovascular
6.5. Others
7. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY END-USER
7.1. Hospitals and Clinics
7.2. Surgical Centers
7.3. Home Care Settings
8. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS) MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. United Kingdom
8.3.2. Germany
8.3.3. France
8.3.4. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. 3M
10.2. ProSolus, Inc.
10.3. Zosano Pharma Corporation
10.4. Medherant Limited
10.5. Tapemark
10.6. Toyochem Co. Ltd.
10.7. Delivra Corp
10.8. Epinamics GmbH
10.9. AdhexPharma
LIST OF FIGURES
LIST OF TABLES
